AstraZeneca (LSE:AZN) enters Q2 with Bank of America projecting $15.4B sales and $2.51 core EPS plus a possible 160 bp margin boost, while striking a partnership with CSPC on siRNA kidney therapies—$30M upfront and options that could lift the deal to ~$1.77B—after shares dipped about 0.6% ahead of results.
Previous Week Recap
- Bank Of America Forecasts Stronger Margin: Bank of America forecasts AZN Q2 sales $15.4B and core EPS $2.51. Bank sees possible 160 bp core margin expansion; notes shares were down ~0.6% ahead of results.
- AstraZeneca, CSPC SiRNA Deal: AstraZeneca partners with CSPC on siRNA kidney therapies. CSPC got $30M upfront; AZN holds options for global rights to one candidate and regional rights to another; deal tops ~$1.77B.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.